Phase 2 Liver Cancer Trial, Recruiting NCT04803318 Sponsor: Second Affiliated Hospital of Guangzhou Medical University Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT04803318
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 85 years old
  • People who have an advanced solid tumor (a type of cancer) that has come back or has not responded to previous treatment
  • People whose doctors estimate they are likely to live for more than three months

Who may not be able to join:

  • People who have a benign tumor (a growth that is not cancerous)
  • People whose doctors estimate they are likely to live for less than three months
  • People who have serious other medical conditions (confirm with trial site for specific details)
  • People who fall into other unspecified categories that may affect eligibility (confirm with trial site for specific details)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zhenfeng Zhang, MD, PhD, Second Affiliated Hospital of Guangzhou Medical University

Phone: +862039195966

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Registry
ClinicalTrials.gov
Start date
1 January 2021
Est. completion
1 January 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov